

# **Carbon Reduction Plan**

Supplier name: Zydus Pharmaceuticals UK Ltd

**Publication date:** August 2025

## **Commitment To Achieving Net Zero**

Zydus Pharmaceuticals UK Ltd, a wholly owned subsidiary of Zydus Lifesciences Limited, is committed to achieving Net Zero emissions in the United Kingdom by 2050.

# **Baseline Emissions Footprint**

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: Financial Year 2021 - 2022

Additional Details relating to the Baseline Emissions calculations.

Zydus Pharmaceuticals UK Ltd is a virtual operation in the UK and was established in 2023. Our emissions data as seen in this Carbon Reduction Plan is reported at a global level by our parent organisation Zydus Lifesciences Ltd.

The calculation tool used for scope 1 and 2 emissions is the United States Environmental Protection Agency and Central Electrical Authority, Govt. of India. Scope 2 emissions are calculated using the location-based method.

Scope 3 emissions account for the following categories as per the GHG protocol:

Category 2 (Capital Goods): Spend Based Method

Category 6 (Business Travel): Spend Based Method

Category 9 (Downstream Transportation and Distribution): Spend Based Method

Category 5 (Waste Generated in Operations): Waste Specific Method

Category 7 (Employee Commuting): Distance Specific Method



Please note, the increase in scope 3 emissions for FY24-25 are due to the additional reporting boundaries in comparison to baseline figures (from 2 categories to 5 categories).

In the current reporting year (FY 24-25) the below theoretical figures represent UK only operations, which are included in the figures reported at group level:

• Total Energy Consumption: 55.26 MWh

• Total GHG Emissions: 9.44 tCO2e

#### Baseline year (FY 2021-2022) emissions: Zydus Lifesciences Limited

EMISSIONS	TOTAL (tCO <sub>2</sub> e)
Scope 1	59,573
Scope 2	191,170
Scope 3	9,072
(Included Sources)	(Emissions from employee commute and business travel only)
Total Emissions	259,815

# **Current Emissions Reporting**

Reporting Year (FY 2024-2025): Zydus Lifesciences Limited		
EMISSIONS	TOTAL (tCO <sub>2</sub> e)	
Scope 1	56,459	
Scope 2	205,172	
Scope 3	66,916	
(Included Sources)	(5 categories)	



Total Emissions	<b>328,547</b> (higher than baseline due to the increase in categories for Scope 3)

# **Emissions Reduction Targets**

As our emissions reporting matures in the following years for our UK based operations, we aim to set appropriate reduction targets to fulfil our commitment of achieving Net Zero by 2050.

Please see the full Zydus Lifesciences Limited report for further details (specifically pages 85-87 Emissions Management) at the following link:

https://www.zyduslife.com/investor/admin/uploads/14/2/2024-2025.pdf

## **Carbon Reduction Projects**

For more information on how Zydus constantly endeavours to create a lasting positive impact on global health and sustainability please refer to below report (pages 76-95):

https://www.zyduslife.com/investor/admin/uploads/14/2/2024-2025.pdf



#### **Declaration and Sign Off**

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard<sup>1</sup> and uses the appropriate Government emission conversion factors for greenhouse gas company reporting<sup>2</sup>.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard<sup>3</sup>.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed: Signed:

Date: Date:

Name: Monica Huang Name: Dr Amrut Naik

Position: Country Head Position: Director

<sup>&</sup>lt;sup>1</sup>https://ghgprotocol.org/corporate-standard

<sup>&</sup>lt;sup>2</sup>https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting

<sup>&</sup>lt;sup>3</sup>https://ghgprotocol.org/standards/scope-3-standard